The Mullally Laboratory studies myeloid blood cancers, with a focus on myeloproliferative neoplasms (MPN). We use a range of approaches including genomics, CRISPR, single-cell technologies, as well as mouse models and cellular biology to advance the understanding of MPN biology, with the goal of translating this into improved treatment options for patients. We are particularly interested in early MPN pathogenesis i.e. clonal hematopoiesis, MPN stem cells, bone marrow fibrosis and developing genetic and cellular therapies to treat MPN.